A Phase 3 interventional study of Open-Label Envudeucitinib and Blinded Envudeucitinib in Plaque Psoriasis, Psoriasis (PsO) and Psoriasis, sponsored by Alumis Inc. Active, not recruiting at 268 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Alumis Inc · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.
Among the 764 studies in Psoriasis with a site in United States, this one is the 12th largest by planned enrollment of the 673 interventional ones that give a count, is one of 25 that started in 2025, is one of 188 in phase 3, reaches primary completion later than 66 of the 85 other live ones, and was the 728th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Modern Research Associates, PLLC · Sites in United States
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
InventisBio Co., Ltd · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
764 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 98 · Phase 2 218 · Phase 3 193 · Phase 4 117
First in 1977; this study’s year is marked. 25 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,680 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 77 across the 673 interventional studies, 200 across the 90 observational. Of the 645 that completed or were terminated, 375 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
524 of 764 have an industry lead sponsor. The 10 most frequent:
Alumis Inc is the lead sponsor of 13 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
Alumis Inc has 5 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
22 of the studies in Psoriasis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05981118Phase 3Wake Forest University Health SciencesComparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) | 2027-01 |
| NCT03987763Bausch Health Americas, Inc.A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis | 2026-11 |
| NCT05570955Wake Forest University Health SciencesDeucravacitinib Adherence Study | 2026-11 |
| NCT04036188Wright State UniversityTriamcinolone With Vitamin D Synergistic Efficacy in Psoriasis | 2026-12 |
| NCT07221890Brigham and Women's HospitalA Trial of Academic Detailing to Promote Prescribing of Biosimilars | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 764 studies in Psoriasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are:
Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-001 twice daily for 24 weeks. After 24 weeks, the first 200 patients meeting at least PASI-75 clinical response will be randomly assigned to receive ESK-001 or placebo. At any point during this time, the patients losing the initial clinical response may return to the open-label ESK-001 treatment. Patients who complete Week 48 will return to open-label ESK-001 treatment and they will receive ESK-001 until the end of the study or discontinuation. All the remaining patients not meeting the entry criteria for the randomized withdrawal phase will continue to receive open-label ESK-001 for the remainder of the study.
Patients taking part in the study must be men or women aged at least 18 years old and have completed a previous (parent) study of ESK-001 in moderate to severe plaque psoriasis.
Patients must consent and agree to:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open-Label ESK-001 administered as an oral tablet
Drug: Open-Label Envudeucitinib
Blinded ESK-001 administered as an oral tablet
Drug: Blinded Envudeucitinib
Matching placebo administered as an oral tablet
Drug: Placebo
Open-Label ESK-001
Blinded ESK-001 during Randomized Treatment Withdrawal Period
Placebo during Randomized Treatment Withdrawal Period
To assess the long-term safety and tolerability of ESK-001 throughout the duration of the study
Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Time frame: Approximately 4 years
To assess the long-term efficacy of ESK-001 using the Psoriasis Area and Severity Index (PASI-75)
Proportion of patients achieving ≥75% reduction in PASI
Time frame: 24, 48, 72, and 96 weeks
To assess the long-term efficacy of ESK-001 using the Psoriasis Area and Severity Index (PASI-90)
Proportion of patients achieving ≥90% reduction in PASI
Time frame: 24, 48, 72, and 96 weeks
To assess the long-term efficacy of ESK-001 using the Psoriasis Area and Severity Index (PASI-100)
Proportion of patients achieving 100% reduction in PASI
Time frame: 24, 48, 72, and 96 weeks
To assess the long-term efficacy of ESK-001 using the Static Physician's Global Assessment (sPGA 0/1)
Proportion of patients achieving a score of 0 or 1 on sPGA
Time frame: 24, 48, 72, and 96 weeks
To assess the long-term efficacy of ESK-001 based on change in Psoriasis Area and Severity Index (PASI)
Change in Psoriasis Area and Severity Index (PASI) from baseline assessments
Time frame: 24, 48, 72, and 96 weeks
To assess the long-term efficacy of ESK-001 based on change in Affected Body Surface Area (%BSA)
Change in affected body surface area (%BSA) from baseline assessments
Time frame: 24, 48, 72, and 96 weeks
To characterize the loss of PASI-75 response following withdrawal of ESK-001 treatment (only for patients randomized to the treatment withdrawal phase)
Median time to loss of PASI-75 response
Time frame: Week 48
To characterize the loss of PASI-90 response following withdrawal of ESK-001 treatment (only for patients randomized to the treatment withdrawal phase)
Median time to loss of PASI-90 response
Time frame: Week 48
To characterize the loss of sPGA-0/1 response following withdrawal of ESK-001 treatment (only for patients randomized to the treatment withdrawal phase)
Median time to loss of sPGA-0/1 response
Time frame: Week 48
To assess the change in quality of life (QoL) using Dermatology Life Quality Index after long-term ESK-001 administration
Proportion of patients achieving a DLQI-0/1 score of 0 (no effect) or 1 (minimal effect)
Time frame: Week 24, Week 48, and Week 72
Showing the first 100 of 268 sites across 16 countries. Choose a country and city above to see the rest.
Plan to share: Undecided — The Sponsor Alumis Inc. is a clinical-stage biopharmaceutical company that has not yet adopted an Individual Participant Data (IPD) sharing plan.
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Nov 2028, 46 months after the start.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 46 months is above that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alumis Inc